Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Fast Forward

Trump’s ‘gift from God’ drug, espoused by Jewish doctor, does not prevent coronavirus: study

Hydroxychloroquine, the anti-malaria drug touted by President Donald Trump as a treatment for Covid-19 — and taken by him to prevent contracting the disease — does not prevent against coronavirus infection when taken prophylactically, a new study found.

The study, published Wednesday in the New England Journal of Medicine, is the first double-blind, placebo-controlled study of the drug, meaning that neither the researchers administering the drug to research subjects, nor the subjects themselves, knew if they were taking hydroxychloroquine or a simple vitamin supplement. That methodology is considered the “gold standard” of medical research.

Dr. Vladimir Zelenko, a Hasidic doctor in New York who has made it his mission to promote the use of hydroxychloroquine to prevent hospitalization by using it to treat high-risk individuals with early symptoms, both criticized the study and touted the fact that it found that the drug is safe overall.

Zelenko’s approach, of prescribing hydroxychloroquine at the earliest signs of Covid-19 symptoms in high-risk individuals, is currently the subject of a controlled study at a hospital on Long Island, which will not release its results until next year.

Zelenko has advised other countries to use the drug prophylactically, however, and said that he took it himself to prevent infection, because he is immunocompromised.

The study’s subjects, who were mailed either the drug or the placebo immediately after being exposed to a Covid-19 patient, were front-line medical workers and first responders. Of the 821 people included in the study’s final results, 88% had high-risk exposures; 12% of the people taking hydroxychloroquine contracted the disease, compared with 14% of those taking the placebo. The study authors concluded that this was not a statistically meaningful difference.

The study did find that the drug, overall, is safe, citing no instances of serious side affects besides nausea and diarrhea. Previous analyses of observational data of hospitalized patients taking the drug found heightened risks of cardiac arrest compared with no use of the drug.

Ari Feldman is a staff writer at the Forward. Contact him at [email protected] or follow him on Twitter @aefeldman

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and the protests on college campuses.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

Make a gift of any size and become a Forward member today. You’ll support our mission to tell the American Jewish story fully and fairly. 

— Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.